================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 29, 2004
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure.
On March 29, 2004, the Company issued a press release announcing that
during the American Association of Cancer Research annual meeting currently
underway in Orlando, Fla., several of its customers from major research
institutions worldwide will present results in which the Company's WAVE System
has played an important role. A copy of the press release is filed herewith as
Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated March 29, 2004, announcing that during the American
Association of Cancer Research annual meeting currently underway in
Orlando, Fla., several of its customers from major research institutions
worldwide will present results in which the Company's WAVE System has
played an important role.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Michael J. Draper
------------------------------------------
Michael J. Draper, Chief Financial Officer
March 29, 2004
3